Clinical and Hemodynamic Responses to Imatinib in Pulmonary Veno-Occlusive Disease/Pulmonary Capillary Hemangiomatosis: A Retrospective Pilot Study of Five Cases and Review of the Literature.
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
accepted:
27
02
2023
medline:
8
5
2023
pubmed:
31
3
2023
entrez:
30
3
2023
Statut:
ppublish
Résumé
Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare types of pulmonary arterial hypertension with dismal prognoses; there is no established medical treatment for these conditions. Possible efficacy of imatinib against these conditions has been reported in 15 cases; however, how and in whom imatinib is effective remain unknown. We retrospectively evaluated clinical data from consecutive patients with PVOD/PCH treated with imatinib at our institution. The diagnosis of PVOD/PCH was established using the following criteria: pre-capillary pulmonary hypertension; diffusion capacity of the lung for carbon monoxide < 60%; and two or more high-resolution computed tomography findings of interlobular septal thickening, centrilobular opacities, and mediastinal lymphadenopathy. The dose of pulmonary vasodilators remained unchanged during the assessment of imatinib. The medical records of five patients with PVOD/PCH were reviewed. The patients were aged 67 ± 13 years, their diffusion capacity of the lung for carbon monoxide was 29 ± 8%, and their mean pulmonary artery pressure was 40 ± 7 mmHg. Imatinib was administered at 50-100 mg/day; consequently, the World Health Organization functional class improved in one patient. In addition, imatinib improved the arterial oxygen partial pressure in this and another patient (these two also experienced a decreased mean pulmonary artery pressure and pulmonary vascular resistance after imatinib usage). This study indicated that imatinib improves the clinical condition, including pulmonary hemodynamics, of some patients with PVOD/PCH. In addition, patients with a certain high-resolution computed tomography pattern or PCH-dominant vasculopathy may respond favorably to imatinib.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare types of pulmonary arterial hypertension with dismal prognoses; there is no established medical treatment for these conditions. Possible efficacy of imatinib against these conditions has been reported in 15 cases; however, how and in whom imatinib is effective remain unknown.
METHODS
METHODS
We retrospectively evaluated clinical data from consecutive patients with PVOD/PCH treated with imatinib at our institution. The diagnosis of PVOD/PCH was established using the following criteria: pre-capillary pulmonary hypertension; diffusion capacity of the lung for carbon monoxide < 60%; and two or more high-resolution computed tomography findings of interlobular septal thickening, centrilobular opacities, and mediastinal lymphadenopathy. The dose of pulmonary vasodilators remained unchanged during the assessment of imatinib.
RESULTS
RESULTS
The medical records of five patients with PVOD/PCH were reviewed. The patients were aged 67 ± 13 years, their diffusion capacity of the lung for carbon monoxide was 29 ± 8%, and their mean pulmonary artery pressure was 40 ± 7 mmHg. Imatinib was administered at 50-100 mg/day; consequently, the World Health Organization functional class improved in one patient. In addition, imatinib improved the arterial oxygen partial pressure in this and another patient (these two also experienced a decreased mean pulmonary artery pressure and pulmonary vascular resistance after imatinib usage).
CONCLUSIONS
CONCLUSIONS
This study indicated that imatinib improves the clinical condition, including pulmonary hemodynamics, of some patients with PVOD/PCH. In addition, patients with a certain high-resolution computed tomography pattern or PCH-dominant vasculopathy may respond favorably to imatinib.
Identifiants
pubmed: 36995544
doi: 10.1007/s40256-023-00577-6
pii: 10.1007/s40256-023-00577-6
doi:
Substances chimiques
Imatinib Mesylate
8A1O1M485B
Carbon Monoxide
7U1EE4V452
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
329-338Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61:2200879. https://doi.org/10.1183/13993003.00879-2022 .
doi: 10.1183/13993003.00879-2022
pubmed: 36028254
Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. Chest. 2000;118:1671–9. https://doi.org/10.1378/chest.67.4.487 .
doi: 10.1378/chest.67.4.487
pubmed: 11115457
Montani D, Girerd B, Jaïs X, Levy M, Amar D, Savale L, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med. 2017;5:125–34. https://doi.org/10.1016/S2213-2600(16)30438-6 .
doi: 10.1016/S2213-2600(16)30438-6
pubmed: 28087362
Ogawa A, Sakao S, Tanabe N, Matsubara H, Tatsumi K. Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a systematic review. Respir Investig. 2019;57:183–90. https://doi.org/10.1016/j.resinv.2018.10.004 .
doi: 10.1016/j.resinv.2018.10.004
pubmed: 30473253
Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47:1518–34. https://doi.org/10.1183/13993003.00026-2016 .
doi: 10.1183/13993003.00026-2016
pubmed: 27009171
Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412–3. https://doi.org/10.1056/NEJMc051946 .
doi: 10.1056/NEJMc051946
pubmed: 16192491
Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127:1128–38. https://doi.org/10.1161/CIRCULATIONAHA.112.000765 .
doi: 10.1161/CIRCULATIONAHA.112.000765
pubmed: 23403476
Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008;32:232–5. https://doi.org/10.1183/09031936.00054407 .
doi: 10.1183/09031936.00054407
pubmed: 18591341
Adachi S, Hirashiki A, Kondo T, Nakaguro M, Ogawa A, Miyaji K, et al. Imatinib is partially effective for the treatment of pulmonary capillary hemangiomatosis. Intern Med. 2014;53:603–7. https://doi.org/10.2169/internalmedicine.53.1157 .
doi: 10.2169/internalmedicine.53.1157
pubmed: 24633031
Nayyar D, Muthiah K, Kumarasinghe G, Hettiarachchi R, Celermajer D, Kotlyar E, et al. Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis. Pulm Circ. 2014;4:342–5. https://doi.org/10.1086/675996 .
doi: 10.1086/675996
pubmed: 25006453
pmcid: 4070788
Ogawa A, Miyaji K, Matsubara H. Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Respir Med. 2017;131:215–9. https://doi.org/10.1016/j.rmed.2017.08.032 .
doi: 10.1016/j.rmed.2017.08.032
pubmed: 28947033
Sato H, Sugimura K, Miura M, Konno R, Kozu K, Yaoita N, et al. Beneficial effects of imatinib in a patient with suspected pulmonary veno-occlusive disease. Tohoku J Exp Med. 2019;247:69–73. https://doi.org/10.1620/tjem.247.69 .
doi: 10.1620/tjem.247.69
pubmed: 30700638
Koiwa H, Tsujino I, Ikeda D, Ohira H, Tanino M, Nishimura M. An autopsy case of pulmonary veno-occlusive disease refractory to imatinib. Eur Respir J. 2011;37:968–70. https://doi.org/10.1183/09031936.00095710 .
doi: 10.1183/09031936.00095710
pubmed: 21454902
Kataoka M, Yanagisawa R, Fukuda K, Yoshino H, Satoh T. Sorafenib is effective in the treatment of pulmonary veno-occlusive disease. Cardiology. 2012;123:172–4. https://doi.org/10.1159/000342787 .
doi: 10.1159/000342787
pubmed: 23128832
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75. https://doi.org/10.1183/13993003.01032-2015 .
doi: 10.1183/13993003.01032-2015
pubmed: 26318161
Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, et al. Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017). Circ J. 2019;83:842–945. https://doi.org/10.1253/circj.CJ-66-0158 .
doi: 10.1253/circj.CJ-66-0158
pubmed: 30853682
Wada H, Nakajima T, Suzuki H, Anazawa R, Narita T, Terada J, et al. Pulmonary capillary hemangiomatosis diagnosed by pathology of explanted lungs: a unique etiology serves as a key of clinical diagnosis. Gen Thorac Cardiovasc Surg. 2019;67:332–5. https://doi.org/10.1007/s11748-018-0950-x .
doi: 10.1007/s11748-018-0950-x
pubmed: 29804176
Anazawa R, Terada J, Sakao S, Shigeta A, Tanabe N, Tatsumi K. Features of radiological and physiological findings in pulmonary capillary hemangiomatosis: an updated pooled analysis of confirmed diagnostic cases. Pulm Circ. 2019;9:1–8. https://doi.org/10.1177/2045894019896696 .
doi: 10.1177/2045894019896696